Brokerages Set Pliant Therapeutics, Inc. Price Target at 40.57
| PLRX Stock | USD 13.17 0.38 2.97% |
Slightly above 54% of Pliant Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Pliant Therapeutics suggests that some traders are interested. Pliant Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Pliant Therapeutics' earnings reports, geopolitical events, and overall market trends.
Pliant |
Shares of Pliant Therapeutics, Inc. have earned a consensus recommendation of Buy from the nine research firms that are covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price
Read at thelincolnianonline.com
 |
Pliant Therapeutics Fundamental Analysis
We analyze Pliant Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pliant Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pliant Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Pliant Therapeutics is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Pliant Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pliant Therapeutics stock to make a market-neutral strategy. Peer analysis of Pliant Therapeutics could also be used in its relative valuation, which is a method of valuing Pliant Therapeutics by comparing valuation metrics with similar companies.
Peers
Pliant Therapeutics Related Equities
| SNDX | Syndax Pharmaceuticals | 5.59 | ||||
| STOK | Stoke Therapeutics | 2.13 | ||||
| RVMD | Revolution Medicines | 1.32 | ||||
| ARVN | Arvinas | 0.89 | ||||
| ETNB | 89bio | 0.39 | ||||
| CYTK | Cytokinetics | 0.23 | ||||
| DYN | Dyne Therapeutics | 0.38 | ||||
| BDTX | Black Diamond | 0.47 | ||||
| MDGL | Madrigal Pharmaceuticals | 0.98 | ||||
| RLAY | Relay Therapeutics | 1.44 | ||||
| INZY | Inozyme Pharma | 1.77 | ||||
| VRDN | Viridian Therapeutics | 1.89 | ||||
| ACLX | Arcellx | 2.12 | ||||
| PASG | Passage Bio | 14.93 |
Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.